Dawn Duss, MD
Pediatric Ophthalmology and Strabismus Specialist · Ponte Vedra Beach, FLNPI 1316958846
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,500 of the $8,648 with a category attached, or 75.2%. Amgen accounts for 96.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $3,339 and has fallen 89.6% since, to $348 in 2025.
Across 70 payments — averaging $123.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$8K
- Sun Pharmaceutical Industries Inc.$114
- Kala Pharmaceuticals, Inc.$102
- Ocular Therapeutix, Inc.$62
- Tarsus Pharmaceuticals, Inc.$24
- Travere Therapeutics, Inc.$12
- plus $7 from 1 others
Across 4 payments — averaging $3071.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$12K
What the payments were for
- Consulting fees$501%
- Speaking & faculty fees$6,50075%
- Food & beverage$2,05924%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 60 | $8,327 |
| Sun Pharmaceutical Industries Inc. | 1 | $114 |
| Kala Pharmaceuticals, Inc. | 1 | $102 |
| Ocular Therapeutix, Inc. | 2 | $62 |
| Tarsus Pharmaceuticals, Inc. | 1 | $24 |
| Travere Therapeutics, Inc. | 2 | $12 |
| NEW World Medical,inc. | 3 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pediatric ophthalmology and strabismus specialist providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 26 | $882 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 44 | $491 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $89 |
Paid to pharmacies, not to this prescriber.
Other pediatric ophthalmology and strabismus specialist in Ponte Vedra Beach
- Austin BachHollywood$12K
- Robert GoldMaitland$3K
- Louis BlumenfeldMaitland$2K
- Mariana Abi KaramMiami$2K
- Vikisha HazariwalaMaitland$1K
- Scott SilvermanBradenton$908
- Megha PansaraTampa$310
- Tiffany KrugerCrestview$246
- Robert HeredMaitland$211
- Nehemiah SpencerMiami$184
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.